INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 45m ago
HOUSE PTR5m ago
SEC 13F5m ago
ROBINHOOD CHAIN5m ago
Public company

RXRXRECURSION PHARMACEUTICALS, INC.

CIK 0001601830

EDGAR filingsOpen in network
Disclosed transactions49
Buys / sells0 / 18
Max Insider Score24
Connections8with evidence

RXRX · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
HF
Hassan FredDirector
RXRXRECURSION PHARMACEUTICALS, INC.
Grant or award
A—
156.7K sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2836 · Biological Products, (No Diagnostic Substances) · Nov 4, 2026
  • ← Insider ofevidence
    Hassan FredDirector · Nov 4, 2026
  • ← Insider ofevidence
    Bumpus NamandjeDirector · Jun 4, 2026
  • ← Insider ofevidence
    Hallett DavidChief Scientific Officer · May 19, 2026
4
BB
Borgeson BlakeDirector
RXRXRECURSION PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL
$155K
40.0K sh
Nov 3, 2026
Nov 4, 2026
traded Nov 3, 2026
+1d
SEC FORM 4

Evidence

12
HD
Hallett DavidChief Scientific Officer
RXRXRECURSION PHARMACEUTICALS, INC.
Tax withholding
F$84K
26.7K sh
Aug 17, 2026Aug 18, 2026
traded Aug 17, 2026
+1dSEC FORM 4

Evidence

11
KN
Khan NajatDirector, CEO and President
RXRXRECURSION PHARMACEUTICALS, INC.
Tax withholding
F$254K
80.5K sh
Aug 17, 2026Aug 18, 2026
traded Aug 17, 2026
+1dSEC FORM 4

Evidence

0
GC
Gibson ChristopherDirector
RXRXRECURSION PHARMACEUTICALS, INC.
Derivative conversion · 10b5-1 plan
C—
40.0K sh
Jun 5, 2026Jun 5, 2026
traded Jun 5, 2026
+0dSEC FORM 4

Evidence

23
KN
Khan NajatDirector, CEO and President
RXRXRECURSION PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$84K
23.6K sh
Jun 5, 2026Jun 5, 2026
traded Jun 5, 2026
+0dSEC FORM 4

Evidence

16
GC
Gibson ChristopherDirector
RXRXRECURSION PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$145K
40.0K sh
Jun 5, 2026Jun 5, 2026
traded Jun 5, 2026
+0dSEC FORM 4

Evidence

0
GC
Gibson ChristopherDirector
RXRXRECURSION PHARMACEUTICALS, INC.
Derivative conversion · 10b5-1 plan
C—
40.0K sh
Jun 5, 2026Jun 5, 2026
traded Jun 5, 2026
+0dSEC FORM 4

Evidence

24
BN
Bumpus NamandjeDirector
RXRXRECURSION PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$16K
4,386 sh
Jun 3, 2026Jun 4, 2026
traded Jun 3, 2026
+1dSEC FORM 4

Evidence

19
BB
Borgeson BlakeDirector
RXRXRECURSION PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$110K
30.0K sh
Jun 2, 2026Jun 4, 2026
traded Jun 2, 2026
+2dSEC FORM 4

Evidence

12
KN
Khan NajatDirector, CEO and President
RXRXRECURSION PHARMACEUTICALS, INC.
Tax withholding
F$191K
62.7K sh
May 15, 2026May 19, 2026
traded May 15, 2026
+4dSEC FORM 4

Evidence

12
HD
Hallett DavidChief Scientific Officer
RXRXRECURSION PHARMACEUTICALS, INC.
Tax withholding
F$81K
26.7K sh
May 15, 2026May 19, 2026
traded May 15, 2026
+4dSEC FORM 4

Evidence

9
BB
Borgeson BlakeDirector
RXRXRECURSION PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$106K
30.0K sh
May 5, 2026May 7, 2026
traded May 5, 2026
+2dSEC FORM 4

Evidence

6
GC
Gibson ChristopherDirector
RXRXRECURSION PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$144K
40.0K sh
Apr 22, 2026Apr 24, 2026
traded Apr 22, 2026
+2dSEC FORM 4

Evidence

0
GC
Gibson ChristopherDirector
RXRXRECURSION PHARMACEUTICALS, INC.
Derivative conversion · 10b5-1 plan
C—
40.0K sh
Apr 22, 2026Apr 24, 2026
traded Apr 22, 2026
+2dSEC FORM 4

Evidence

0
GC
Gibson ChristopherDirector
RXRXRECURSION PHARMACEUTICALS, INC.
Derivative conversion · 10b5-1 plan
C—
40.0K sh
Apr 22, 2026Apr 24, 2026
traded Apr 22, 2026
+2dSEC FORM 4

Evidence

6
GC
Gibson ChristopherDirector
RXRXRECURSION PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$124K
40.0K sh
Apr 7, 2026Apr 8, 2026
traded Apr 7, 2026
+1dSEC FORM 4

Evidence

0
GC
Gibson ChristopherDirector
RXRXRECURSION PHARMACEUTICALS, INC.
Derivative conversion · 10b5-1 plan
C—
40.0K sh
Apr 7, 2026Apr 8, 2026
traded Apr 7, 2026
+1dSEC FORM 4

Evidence

8
TR
Taylor Ben RChief Financial Officer
RXRXRECURSION PHARMACEUTICALS, INC.
Tax withholding
F$149K
48.0K sh
Apr 6, 2026Apr 8, 2026
traded Apr 6, 2026
+2dSEC FORM 4

Evidence

9
BB
Borgeson BlakeDirector
RXRXRECURSION PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$93K
30.0K sh
Apr 7, 2026Apr 8, 2026
traded Apr 7, 2026
+1dSEC FORM 4

Evidence

0
GC
Gibson ChristopherDirector
RXRXRECURSION PHARMACEUTICALS, INC.
Derivative conversion · 10b5-1 plan
C—
40.0K sh
Apr 7, 2026Apr 8, 2026
traded Apr 7, 2026
+1dSEC FORM 4

Evidence

0
GC
Gibson ChristopherDirector
RXRXRECURSION PHARMACEUTICALS, INC.
Derivative conversion · 10b5-1 plan
C—
40.0K sh
Jan 20, 2026Jan 22, 2026
traded Jan 20, 2026
+2dSEC FORM 4

Evidence

0
GC
Gibson ChristopherDirector
RXRXRECURSION PHARMACEUTICALS, INC.
Derivative conversion · 10b5-1 plan
C—
40.0K sh
Jan 20, 2026Jan 22, 2026
traded Jan 20, 2026
+2dSEC FORM 4

Evidence

9
GC
Gibson ChristopherDirector
RXRXRECURSION PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$179K
40.0K sh
Jan 20, 2026Jan 22, 2026
traded Jan 20, 2026
+2dSEC FORM 4

Evidence

17
BB
Borgeson BlakeDirector
RXRXRECURSION PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$959K
220.0K sh
Jan 6, 2026Jan 8, 2026
traded Jan 6, 2026
+2dSEC FORM 4

Evidence

14
GC
Gibson ChristopherDirector
RXRXRECURSION PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$170K
40.0K sh
Jan 5, 2026Jan 7, 2026
traded Jan 5, 2026
+2dSEC FORM 4

Evidence

0
GC
Gibson ChristopherDirector
RXRXRECURSION PHARMACEUTICALS, INC.
Derivative conversion · 10b5-1 plan
C—
60.0K sh
Jan 5, 2026Jan 7, 2026
traded Jan 5, 2026
+2dSEC FORM 4

Evidence

0
GC
Gibson ChristopherDirector
RXRXRECURSION PHARMACEUTICALS, INC.
Derivative conversion · 10b5-1 plan
C—
60.0K sh
Jan 5, 2026Jan 7, 2026
traded Jan 5, 2026
+2dSEC FORM 4

Evidence

0
GC
Gibson ChristopherDirector
RXRXRECURSION PHARMACEUTICALS, INC.
Gift · 10b5-1 plan
G—
20.0K sh
Jan 5, 2026Jan 7, 2026
traded Jan 5, 2026
+2dSEC FORM 4

Evidence

18
TR
Taylor Ben RChief Financial Officer
RXRXRECURSION PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$89K
21.4K sh
Dec 29, 2025Dec 30, 2025
traded Dec 29, 2025
+1dSEC FORM 4

Evidence

0
GC
Gibson ChristopherDirector, Chief Executive Officer
RXRXRECURSION PHARMACEUTICALS, INC.
Derivative conversion · 10b5-1 plan
C—
40.0K sh
Dec 19, 2025Dec 19, 2025
traded Dec 19, 2025
+0dSEC FORM 4

Evidence

0
GC
Gibson ChristopherDirector, Chief Executive Officer
RXRXRECURSION PHARMACEUTICALS, INC.
Derivative conversion · 10b5-1 plan
C—
40.0K sh
Dec 19, 2025Dec 19, 2025
traded Dec 19, 2025
+0dSEC FORM 4

Evidence

9
GC
Gibson ChristopherDirector, Chief Executive Officer
RXRXRECURSION PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$180K
40.0K sh
Dec 19, 2025Dec 19, 2025
traded Dec 19, 2025
+0dSEC FORM 4

Evidence

0
GC
Gibson ChristopherDirector, Chief Executive Officer
RXRXRECURSION PHARMACEUTICALS, INC.
Derivative conversion · 10b5-1 plan
C—
60.0K sh
Dec 4, 2025Dec 5, 2025
traded Dec 4, 2025
+1dSEC FORM 4

Evidence

9
GC
Gibson ChristopherDirector, Chief Executive Officer
RXRXRECURSION PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$185K
40.0K sh
Dec 4, 2025Dec 5, 2025
traded Dec 4, 2025
+1dSEC FORM 4

Evidence

0
GC
Gibson ChristopherDirector, Chief Executive Officer
RXRXRECURSION PHARMACEUTICALS, INC.
Derivative conversion · 10b5-1 plan
C—
60.0K sh
Dec 4, 2025Dec 5, 2025
traded Dec 4, 2025
+1dSEC FORM 4

Evidence

0
GC
Gibson ChristopherDirector, Chief Executive Officer
RXRXRECURSION PHARMACEUTICALS, INC.
Gift · 10b5-1 plan
G—
20.0K sh
Dec 4, 2025Dec 5, 2025
traded Dec 4, 2025
+1dSEC FORM 4

Evidence

16
BB
Borgeson BlakeDirector
RXRXRECURSION PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$961K
220.0K sh
Dec 2, 2025Dec 4, 2025
traded Dec 2, 2025
+2dSEC FORM 4

Evidence

9
GC
Gibson ChristopherDirector, Chief Executive Officer
RXRXRECURSION PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$166K
40.0K sh
Nov 19, 2025Nov 19, 2025
traded Nov 19, 2025
+0dSEC FORM 4

Evidence

0
GC
Gibson ChristopherDirector, Chief Executive Officer
RXRXRECURSION PHARMACEUTICALS, INC.
Tax withholding · 10b5-1 plan
F$167K
40.4K sh
Nov 17, 2025Nov 19, 2025
traded Nov 17, 2025
+2dSEC FORM 4

Evidence

12
KN
Khan NajatDirector, Chief R&D Commercial Officer
RXRXRECURSION PHARMACEUTICALS, INC.
Tax withholding
F$73K
17.6K sh
Nov 17, 2025Nov 19, 2025
traded Nov 17, 2025
+2dSEC FORM 4

Evidence

0
GC
Gibson ChristopherDirector, Chief Executive Officer
RXRXRECURSION PHARMACEUTICALS, INC.
Derivative conversion · 10b5-1 plan
C—
40.0K sh
Nov 19, 2025Nov 19, 2025
traded Nov 19, 2025
+0dSEC FORM 4

Evidence

0
GC
Gibson ChristopherDirector, Chief Executive Officer
RXRXRECURSION PHARMACEUTICALS, INC.
Derivative conversion · 10b5-1 plan
C—
40.0K sh
Nov 19, 2025Nov 19, 2025
traded Nov 19, 2025
+0dSEC FORM 4

Evidence

0
GC
Gibson ChristopherDirector, Chief Executive Officer
RXRXRECURSION PHARMACEUTICALS, INC.
Derivative conversion · 10b5-1 plan
C—
60.0K sh
Nov 4, 2025Nov 6, 2025
traded Nov 4, 2025
+2dSEC FORM 4

Evidence

2
GC
Gibson ChristopherDirector, Chief Executive Officer
RXRXRECURSION PHARMACEUTICALS, INC.
Gift · 10b5-1 plan
G—
20.0K sh
Nov 4, 2025Nov 6, 2025
traded Nov 4, 2025
+2dSEC FORM 4

Evidence

8
GC
Gibson ChristopherDirector, Chief Executive Officer
RXRXRECURSION PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$208K
40.0K sh
Nov 4, 2025Nov 6, 2025
traded Nov 4, 2025
+2dSEC FORM 4

Evidence

3
GC
Gibson ChristopherDirector, Chief Executive Officer
RXRXRECURSION PHARMACEUTICALS, INC.
Derivative conversion · 10b5-1 plan
C—
60.0K sh
Nov 4, 2025Nov 6, 2025
traded Nov 4, 2025
+2dSEC FORM 4

Evidence

13
KN
Khan NajatDirector, Chief R&D Commercial Officer
RXRXRECURSION PHARMACEUTICALS, INC.
Grant or award
A—
84.9K sh
Nov 5, 2025Nov 6, 2025
traded Nov 5, 2025
+1dSEC FORM 4

Evidence

9
KN
Khan NajatDirector, Chief R&D Commercial Officer
RXRXRECURSION PHARMACEUTICALS, INC.
Grant or award
A—
169.9K sh
Nov 5, 2025Nov 6, 2025
traded Nov 5, 2025
+1dSEC FORM 4

Evidence

  • ← Insider ofevidence
    Taylor Ben RChief Financial Officer · Dec 30, 2025
  • ← Insider ofevidence
    Borgeson BlakeDirector · Dec 4, 2025
  • ← Insider ofevidence
    Khan NajatDirector, Chief R&D Commercial Officer · Nov 6, 2025
  • ← Insider ofevidence
    Gibson ChristopherDirector, Chief Executive Officer · Nov 6, 2025